EFFECTS OF TWO YEARS OF LIRAGLUTIDE TREATMENT ON FATTY LIVER DISEASE IN PATIENTS WITH TYPE 2 DIABETES: ANALYSIS OF THE LEAD-2 EXTENSION TRIAL

EFFECTS OF TWO YEARS OF LIRAGLUTIDE TREATMENT ON FATTY LIVER DISEASE IN PATIENTS WITH TYPE 2 DIABETES: ANALYSIS OF THE LEAD-2 EXTENSION TRIAL

Bibliographic Details
Main Authors:	Armstrong, M, Falahati, A, Houlihan, D, Elbrond, B, Schmidt, W, Gough, S, Newsome, P
Format:	Conference item
Published:	2010

Similar Items

High prevalence of advanced NAFLD in type 2 diabetic patients with unremarkable liver enzymes and effect of liraglutide on NAFLD: meta-analysis of the LEAD Program
by: Armstrong, M, et al.
Published: (2010)

Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: individual patient data meta-analysis of the LEAD program.
by: Armstrong, M, et al.
Published: (2013)

Safety and efficacy of liraglutide in patients with type 2 diabetes with elevated liver enzymes: individual patient data meta-analysis of the LEAD programme
by: Armstrong, M, et al.
Published: (2013)

Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: Individual patient data meta-analysis of the LEAD program
by: Armstrong, M, et al.
Published: (2013)

High Prevalence of Advanced NAFLD in Type 2 Diabetic Patients with Normal Liver Enzymes and Effect of Liraglutide on NAFLD: Meta-Analysis of the LEAD Program
by: Armstrong, M, et al.
Published: (2010)

Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study.
by: Nauck, M, et al.
Published: (2009)

Liraglutide: from clinical trials to clinical practice.
by: Gough, S
Published: (2012)

Liraglutide in Children and Adolescents with Type 2 Diabetes
by: Tamborlane, William V., et al.
Published: (2019)

Liraglutide add-on to metformin improves postprandial glucose control compared with metformin monotherapy in patients with Type 2 diabetes: posthoc analysis of the Liraglutide Effect and Action in Diabetes (LEAD)2 study
by: Stephens, J, et al.
Published: (2014)

Liraglutide More Effectively Achieves a Composite Endpoint for A1C, SBP and Weight Change Than Other Diabetes Therapies
by: Zinman, B, et al.
Published: (2009)

Long-term sustained glycaemic control with liraglutide and glimepiride (both plus metformin), with added benefits of weight loss and less hypoglycaemia with liraglutide: 2-year LEAD-2 data
by: Frid, A, et al.
Published: (2009)

Long-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study
by: Nauck, M, et al.
Published: (2013)

Long-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study.
by: Nauck, M, et al.
Published: (2013)

Liraglutide, a human GLP-1 analogue, lowers HbA(1c) independent of weight loss
by: Schmidt, W, et al.
Published: (2009)

The impact of disease stage, indicated by number of previous oral antidiabetic agents, on the clinical benefits of liraglutide in the treatment of type 2 diabetes
by: Garber, A, et al.
Published: (2011)

Liraglutide Is Associated with Reduced Rates of Hypoglycemic Events Versus Glimepiride When Achieving Target HbA(1c)
by: Gough, S, et al.
Published: (2010)

Current therapeutic strategies in non-alcoholic fatty liver disease.
by: Dowman, J, et al.
Published: (2011)

Achieving a clinically relevant composite outcome of an HbA1c of <7% without weight gain or hypoglycaemia in type 2 diabetes: a meta-analysis of the liraglutide clinical trial programme.
by: Zinman, B, et al.
Published: (2012)

Achieving a clinically relevant composite outcome of an HbA1c of <7% without weight gain or hypoglycaemia in type 2 diabetes: A meta-analysis of the liraglutide clinical trial programme
by: Zinman, B, et al.
Published: (2012)

Pathogenesis of non-alcoholic fatty liver disease.
by: Dowman, J, et al.
Published: (2010)

Liraglutide efficacy and action in non-alcoholic steatohepatitis (LEAN): study protocol for a phase II multicentre, double-blinded, randomised, controlled trial
by: Armstrong, M, et al.
Published: (2013)

Reductions in HbA(1c) and the incidence of hypoglycaemic episodes are not affected by renal impairment in patients with type 2 diabetes treated with liraglutide
by: Gough, S, et al.
Published: (2011)

The diagnosis of non-alcoholic fatty liver disease: authors' reply
by: Dowman, J, et al.
Published: (2012)

Non-alcoholic fatty liver disease and diabetes.
by: Hazlehurst, J, et al.
Published: (2016)

Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes
by: Nauck, M, et al.
Published: (2009)

Patient-reported outcomes in patients with type 2 diabetes treated with liraglutide or glimepiride, both as add-on to metformin.
by: Hermansen, K, et al.
Published: (2010)

Liraglutide improves two indicators of beta cell function - HOMA-B and proinsulin:insulin ratio - in a meta-analysis of 6 clinical trials
by: Matthews, DR, et al.
Published: (2010)

Glucagon like peptide 1 analogue, Liraglutide, reduces adipose insulin resistance and hepatic de novo lipogenesis in Nonalcoholic Steatohepatitis: Sub-study results of a phase II randomised-control clinical trial
by: Armstrong, M, et al.
Published: (2013)

Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.
by: Dowman, J, et al.
Published: (2011)

Liraglutide, a human GLP-1 analogue, significantly improves beta cell function in subjects with type 2 diabetes
by: Matthews, DR, et al.
Published: (2008)

Protein-truncating variants in BSN are associated with severe adult-onset 2 obesity, type 2 diabetes and fatty liver disease
by: Zhao, Y, et al.
Published: (2024)

Severe asymptomatic non-alcoholic fatty liver disease in routine diabetes care; a multi-disciplinary team approach to diagnosis and management.
by: Armstrong, M, et al.
Published: (2014)

Liraglutide is associated with a significantly greater improvement in glycaemic control than glimepiride in patients with highest baseline beta cell function
by: Matthews, DR, et al.
Published: (2009)

Liraglutide for patients with non-alcoholic steatohepatitis.
by: Dale, A, et al.
Published: (2016)

Liraglutide, a human GLP-1 analogue, reduces bodyweight in subjects with type 2 diabetes, irrespective of body mass index at baseline
by: Schmitz, O, et al.
Published: (2008)

Advanced non-alcoholic fatty liver disease and adipose tissue fibrosis in patients with Alstrom syndrome.
by: Gathercole, L, et al.
Published: (2016)

Gut-liver axis in nonalcoholic fatty liver disease (NAFLD)
by: Koo, Yolanda Wei Ling
Published: (2023)

Non-alcoholic fatty liver disease
by: Pavlides, M, et al.
Published: (2019)

Achieving glycaemic control and weight loss with incretin-based therapies: a comparison of liraglutide, exenatide, and sitagliptin
by: Zinman, B, et al.
Published: (2011)

Diabetes, plasma glucose and incidence of fatty liver, cirrhosis and liver cancer: A prospective study of 0.5 million people
by: Pang, Y, et al.
Published: (2018)